Adam Feuerstein

Risk of “acute, serious, and life-threatening” heart inflammation is now on the label of Sarepta's gene therapy for Duchenne muscular dystrophy. What happens next?

December will be a consequential month for Agios Pharmaceuticals and its effort to expand the use and sales of its blood-disease drug Pyrukynd.

The CEO of the drugmaker Uniqure told investors at a private dinner that the Trump White House “doesn’t like all the drama” inside the FDA.

This week on "The Readout LOUD" podcast: What does Rick Pazdur's new role mean for the FDA? And how much credit can the president take for lowering GLP-1 drug prices?

Is turmoil at the FDA to blame for drugmakers' setbacks? It's not necessarily that simple.

Sarepta Therapeutics delivered a disastrous third-quarter earnings performance.

Caribou Biosciences said its off-the-shelf CAR-T therapy induced complete and durable remissions in patients with advanced B-cell lymphoma.

George Tidmarsh, the FDA's top drug regulator, has been placed on leave after being accused of abusing his regulatory authority, STAT has learned.

September has seen a remarkable pace of dealmaking that has accelerated the biotech stock rally.

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, potentially fatal, liver toxicity.